Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma

Priority Review Granted with
Prescription Drug User Fee Act (PDUFA) Action Date of November 25, 2023